Evidence map›Paper›PMID 19023451›Full record

ArticleMolecular vision2008

Heterozygous expression of myocilin glaucoma mutants increases secretion of the mutant forms and reduces extracellular processed myocilin.

José-Daniel Aroca-Aguilar, Francisco Sánchez-Sánchez, Francisco Martínez-Redondo, Miguel Coca-Prados, Julio Escribano

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Protein misfolding and mitochondrial dysfunction in glaucoma.Frontiers in cell and developmental biology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Evidence for RPGRIP1 gene as risk factor for primary open angle glaucoma.European journal of human genetics : EJHG · 2011
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

José-Daniel Aroca-AguilarArea de Genética, Facultad de Medicina/Centro Regional de Investigaciones Biomédicas (CRIB), Universidad de Castilla-La Mancha, Albacete, Spain.
Francisco Sánchez-Sánchez
Francisco Martínez-Redondo
Miguel Coca-Prados
Julio Escribano
University of Castilla-La Mancha · ES

Funding

Yale Core Grant For Vision ResearchP30EY000785 · NEI · YALE UNIVERSITY · PI TIAN, NING · 1985 to 2010
$5.8M
DIFFERENTIAL GENE EXPRESSION IN CILIARY EPITHELIUMR01EY004873 · NEI · YALE UNIVERSITY · PI COCA-PRADOS, MIGUEL · 1985 to 2005
$1.7M
NEI NIH HHS EY00785NEI NIH HHS EY04873NEI NIH HHS P30 EY000785NEI NIH HHS R01 EY004873
6 · The paper itself

Abstract

purposeHeterozygous mutations in the myocilin gene (MYOC) cause glaucoma by an unknown mechanism. MYOC encodes an extracellular protein of unidentified function that undergoes intracellular endoproteolytic processing in the secretory pathway. It has been described that co-expression of wild-type/mutant myocilin reduces the secretion of the wild-type protein and that single expression of glaucoma myocilin mutants reduces its proteolytic processing. However, the effect of wild-type myocilin on mutant myocilin secretion and how mutant myocilin affects the proteolytic processing of wild-type myocilin have not been investigated. We herein analyze these two issues.

methodsWe modeled the heterozygous state for 4 missense (E323K, R346T, P370L, D380A) and 1 nonsense (Q368X) myocilin mutants by transiently co-expressing each mutant with the wild-type protein in HEK-293T cells. Recombinant mutant and wild-type myocilin in both culture media and cellular fractions were quantified by western immunoblot and densitometry.

resultsA 24 h transient co-expression of each myocilin mutant with the wild-type protein elicited an augmented secretion of the mutant forms from 1.5 fold (D380A) to 5.4 fold (E323K). Under such conditions, extracellular mutant myocilin represented up to 20% of the total mutant protein. Other than this effect, secreted wild-type myocilin significantly decreased from 2.6 fold (E323K) to 36 fold (Q368X). When myocilin proteolytic processing was enhanced (96 hour co-expression) the extracellular amount of wild-type processed myocilin diminished from approximately 2.1 fold (E323K) to 6.3 fold (P370L). Nonreducing SDS-PAGE indicated that extracellular myocilin resulting from 24 h co-expression of wild-type myocilin and each of the 4 missense mutants forms hetero-oligomers and that glaucoma mutations do not increase the size of myocilin aggregates.

conclusionsIncreased extracellular levels of mutant myocilin expressed in heterozygosis may play a relevant role in glaucoma pathogenesis. This effect is likely the result of intracellular mutant/wild-type myocilin hetero-oligomerization.

Indexed as

HeterozygoteProtein Processing, Post-TranslationalCell LineCytoskeletal ProteinsDNA, ComplementaryExtracellular SpaceEye ProteinsGlaucomaGlycoproteinsHumansModels, BiologicalMutant ProteinsMutationMyocilinProtein Structure, QuaternaryCytoskeletal ProteinsDNA, ComplementaryEye ProteinsGlycoproteinsMutant ProteinsMyocilin

Identifiers

PMID19023451
PMCPMC2585175
OpenAlexW1551274032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.